SAB Biotherapeutics Inc (SABS) — Financial Flexibility Index
SAB Biotherapeutics Inc (SABS) has a Financial Flexibility Index of -0.92x as of June 2026. Free cash flow of $-21.54 Million (operating CF $-24.11 Million minus capex $2.57 Million) represents -1% of total liabilities ($23.43 Million). Check total reinvestment intensity of SAB Biotherapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
SAB Biotherapeutics Inc Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for SAB Biotherapeutics Inc across 7 annual periods. For the full cash flow conversion analysis, see SABS operating cash flow.
Annual Financial Flexibility Index for SAB Biotherapeutics Inc (2019–2025)
Year-by-year free cash flow to debt coverage for SAB Biotherapeutics Inc. Explore SABS operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.06x | $-43.84 Million | $-44.78 Million | $21.32 Million | ▼ -10.4% |
| 2024 | -1.86x | $-33.95 Million | $-34.29 Million | $18.23 Million | ▼ -99.2% |
| 2023 | -0.94x | $-24.92 Million | $-25.12 Million | $26.64 Million | ▲ +12.8% |
| 2022 | -1.07x | $-21.29 Million | $-23.46 Million | $19.85 Million | ▼ -453.4% |
| 2021 | 0.30x | $12.93 Million | $1.99 Million | $42.59 Million | ▼ -76.6% |
| 2020 | 1.30x | $22.74 Million | $10.00 Million | $17.53 Million | ▲ +406.1% |
| 2019 | -0.42x | $-8.61 Million | $-9.21 Million | $20.31 Million | — |